Form 4: Inhibitor Therapeutics CFO James McNulty Acquires 100,000 Stock Options
SEC Form 4 Filing
James McNulty, CFO of Inhibitor Therapeutics, acquired 100,000 stock options on March 16, 2024, which vested immediately.
Summary
- On March 16, 2024, James A. McNulty, the CFO of Inhibitor Therapeutics, Inc., acquired 100,000 stock options.
- The options were granted under the company's 2014 Equity Incentive Plan.
- The exercise price of the options is $0.08.
- The options vested immediately and expire on March 16, 2034.
- McNulty directly owns 100,000 shares of common stock underlying the options.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Positives
- The immediate vesting of the options could incentivize the CFO to perform well.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates an acquisition of stock options by the CFO, which is a common form of executive compensation.
Stakeholder Impact
- The acquisition of stock options by the CFO may have a slight positive impact on shareholder sentiment, as it aligns the CFO's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/16/2024 | Date of transaction: CFO James McNulty acquired 100,000 stock options. |
| 03/16/2024 | Date the common stock options were issued to the Reporting Person pursuant to the Issuer's 2014 Equity Incentive Plan. |
| 03/16/2034 | Expiration date of the stock options. |
| 05/16/2024 | Date of signature on the Form 4 filing. |
Keywords
stock options, Inhibitor Therapeutics, Form 4, CFO, James McNulty, equity incentive plan, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.